Competitor Analysis: Kallikrein Inhibitors 2017

Publisher: La Merie Publishing
Pages: 17
Format: PDF
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0139
Release Date: April of 2017

150.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Kallikrein Inhibitors 2017

The present Competitive Intelligence report about Kallikrein Inhibitors and bradykinin receptor antagonists provides a competitor evaluation in the field of marketed drugs and novel approaches for prophylaxis and treatment of hereditary angioedema (HAE) and new investigational compounds for treatment of diabetic macular edema (DME) as of April 2017.

Inhibitors of kallikrein and antagonists of the bradykinin receptors are based on small molecules, antibodies, proteins, peptides as well as RNA. Based on the commercial success of marketed drugs for prophylaxis of HAE, next generation molecules were designed to improve convenience of mode of administration and frequency of administration. In addition, the use of kallikrein inhibitors for ophthalmic indications is being evaluated with the most advanced compounds in clinical studies.

The report includes a compilation of currently active projects in research and development of small molecule, antibody, protein, peptide and oligonucleotide inhibitors ofkallikrein. In addition, the report lists company-specific R&D pipelines of plasma and tissue kallikrein inhibitors. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Competitor Analysis: Kallikrein Inhibitors 2017

Table of Contents

1) Kallikrein Inhibitors 2017

  • Plasma Kallikrein Inhibitors for Hereditary Angioedema
  • Plasma Kallikrein Inhibitors for Diabetic Macular Edema
  • Tissue Kallikrein Inhibitors

2) Corporate Kallikrein Inhibitor R&D Pipelines

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up